Rihova Zuzana, Jancova Eva, Merta Miroslav, Rysava Romana, Reiterova Jana, Zabka Jiri, Tesar Vladimir
Nephrology Unit, 1st Medical Faculty, Charles University, Prague, Czech Republic.
Kidney Blood Press Res. 2005;28(3):144-52. doi: 10.1159/000085854. Epub 2005 May 20.
Despite treatment, renal involvement in antineutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis is still associated with significant long-term mortality and remains an important cause of end-stage renal failure.
We retrospectively analyzed a series of 61 consecutive patients with newly diagnosed ANCA-associated renal vasculitis (54.1% Wegener's granulomatosis, 23% renal-limited vasculitis, 16.4% microscopic polyangiitis, 4.9% Churg-Strauss syndrome) diagnosed between 1986 and 1997.
The median creatinine level at diagnosis was 221.5 (63-762) micromol/l, i.e. 2.5 (0.7-8.6) mg/dl, 32.8% were dialysis-dependent. All patients were treated with cyclophosphamide. Remission was achieved in 87% of patients. Relapses occurred in 44.7%. The median renal disease-free interval was 62.5 (0-138) months. The estimated patient survival at 5 and 10 years was 78.3 and 62.2%, respectively. Mortality was associated with age (p = 0.04 when age limit 50 years) and advanced renal failure (p = 0.038 when compared dialysis-dependent and independent patients). Estimated renal survival time at 5 and 10 years was 69.2 and 55.8%, respectively. At the end of follow-up, 50.8% of patients were in complete remission, 31% had died. The median serum creatinine level was 137.5 (77-469) micromol/l, i.e. 1.56 (0.87-5.3) mg/dl, 24.6% of patients were on regular dialysis treatment.
Patient survival, relapse rate and mortality were comparable to similar reports. In view of the severity of the renal disease and the length of follow-up, renal survival was very good. Despite effective treatment, the long-term outcome of patients with ANCA-associated renal vasculitis remains unsatisfactory.
尽管接受了治疗,但抗中性粒细胞胞浆抗体(ANCA)阳性血管炎患者的肾脏受累仍与显著的长期死亡率相关,并且仍然是终末期肾衰竭的重要原因。
我们回顾性分析了1986年至1997年间连续诊断的61例新诊断的ANCA相关性肾血管炎患者(54.1%为韦格纳肉芽肿病,23%为局限于肾脏的血管炎,16.4%为显微镜下多血管炎,4.9%为变应性肉芽肿性血管炎)。
诊断时肌酐水平中位数为221.5(63 - 762)微摩尔/升,即2.5(0.7 - 8.6)毫克/分升,32.8%的患者依赖透析。所有患者均接受环磷酰胺治疗。87%的患者实现缓解。复发率为44.7%。无肾脏疾病的中位间隔时间为62.5(0 - 138)个月。5年和10年的预计患者生存率分别为78.3%和62.2%。死亡率与年龄相关(年龄限制为50岁时p = 0.04)以及晚期肾衰竭相关(比较依赖透析和不依赖透析的患者时p = 0.038)。5年和10年的预计肾脏生存时间分别为69.2%和55.8%。随访结束时,50.8%的患者完全缓解,31%的患者死亡。血清肌酐水平中位数为137.5(77 - 469)微摩尔/升,即1.56(0.87 - 5.3)毫克/分升,24.6%的患者接受定期透析治疗。
患者生存率、复发率和死亡率与类似报告相当。鉴于肾脏疾病的严重程度和随访时间,肾脏生存率非常好。尽管治疗有效,但ANCA相关性肾血管炎患者的长期预后仍不令人满意。